Skip to content Skip to footer
Subscribe Now
PharmaShots Interview Jon Heinrichs of Sanofi Pasteur & Tonya Villafana of AstraZeneca Shares Insights on Nirsevimab in Healthy Infants Born at Term or Late Preterm
VIEWPOINTS

PharmaShots Interview: Jon Heinrichs of Sanofi Pasteur & Tonya Villafana of AstraZeneca Shares Insights on Nirsevimab in Healthy Infants Born at Term or Late Preterm

In an interview with PharmaShots, Jon Heinrichs, Associate, Vice President, and the Head of Innovation and Emerging Sciences at Sanofi Pasteur & Tonya Villafana, Vice President, Global Franchise Head, Infection at AstraZeneca share their views on the data of Nirsevimab in P-III (MELODY) trial to protect infants against Respiratory Syncytial Virus Shots: The P-III (MELODY) trial evaluates nirsevimab (50/100mg, IM) vs…
April 19, 2022

Read more

PharmaShots' Key Highlights of First Quarter 2022
INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2022

The first quarter of 2022 highlights the approvals, clinical data & acquisitions. There are major alliances in this quarter which include Biocon acquired Viatris’ biosimilars assets for ~$3.335B, Stryker signed a definitive agreement to acquire Vocera Communications for ~$3.09B, Biohaven acquire Channel Biosciences for ~$3B The first quarter of the year also showcases regulatory events…
March 31, 2022

Read more

Life Sciences Deals Top 20 2021
TOP 20

Top 20 Life Sciences Deals of 2021 by Total Deal Value

Shots: The life science industry saw high deal activity in 2021 staying in the range of an even busier 2020. Fourth-quarter 2021 set the tone with Recursion’s development and commercialization deal with Roche and Genentech for a total value of $12.7B, followed by Poseida Therapeutics’ development and commercialization deal with Takeda for $3.73B. This article is based on the 2021…
February 10, 2022

Read more

Viewpoints_Alexander Bedenkov
VIEWPOINTS

PharmaShots Interview: AstraZeneca’s Alexander Bedenkov Shares Insight on First Virtual Events with Slush to Improve Patients Outcomes

In an interview with PharmaShots, Alexander Bedenkov, Vice President, Medical International Region & Global Health Innovation Hubs (A.Catalyst) Network Head at AstraZeneca shares his views on the First Virtual Events in collaboration with Slush to accelerate better health outcomes through innovation Shots: The companies collaborated to launch virtual events and enhance collaboration in the healthcare sector. The event was run through AstraZeneca’s A.Catalyst Network,…
December 13, 2021

Read more

Viewpoints_Dr. Barbara Klencke
VIEWPOINTS

PharmaShots Interview: Sierra Oncology Dr. Barbara Klencke Shares Insight on Sierra’s Agreement with AstraZeneca for AZD5153

In an interview with PharmaShots, Dr. Barbara Klencke, MD, Chief Medical Officer at Sierra Oncology share her views on the license agreement for AZD5153 with AstraZeneca to treat myelofibrosis Shots: AstraZeneca signs an exclusive license agreement with Sierra for AZD5153 to expand myelofibrosis pipeline. The agreement will provide a novel compound into Sierra's pipeline to supply therapies for rare cancers Sierra plans…
October 11, 2021

Read more

Load more